Literature DB >> 19485299

Submacular combination treatment for management of acute, massive submacular hemorrhage in age-related macular degeneration.

Sumit P Shah1, Jean Pierre Hubschman, Christine R Gonzales, Steven D Schwartz.   

Abstract

A surgical technique is described combining submacular anti-vascular endothelial growth factor (anti-VEGF) and recombinant tissue plasminogen activator (r-TPA) with pneumatic displacement of massive submacular hemorrhage in age-related macular degeneration. An 84-year-old man with a large, acute submacular hemorrhage secondary to age-related macular degeneration underwent combination vitrectomy, submacular anti-VEGF and r-TPA injection with pneumatic displacement of the hemorrhage. At the last follow-up visit, 7 months after surgery, visual acuity was 20/80 with a small fibrovascular pigment epithelial detachment and atrophic retinal pigment epithelial changes. A 77-year-old woman with known age-related macular degeneration underwent a similar surgical procedure for a similar acute, large submacular hemorrhage related to age-related macular degeneration. Nine months after surgery, the visual acuity was 20/70(-1). Combination submacular anti-VEGF therapy delivered at the time of pars plana vitrectomy and submacular tissue plasminogen activator assisted hemorrhage displacement may be a viable treatment strategy for the management massive submacular hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19485299     DOI: 10.3928/15428877-20090430-16

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  2 in total

1.  Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results.

Authors:  Abdullah Ozkaya; Zeynep Alkin; Ihsan Yilmaz; Ahmet Taylan Yazici
Journal:  Saudi J Ophthalmol       Date:  2014-12-13

2.  Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration.

Authors:  Sachin Jain; Kamal Kishore; Yog Raj Sharma
Journal:  Indian J Ophthalmol       Date:  2013-09       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.